In addition, a synthetic bacterial lipoprotein (a TLR1/TLR2 agonist) was reported to reduce the suppressive function of Foxp3+ Treg cells and enhance the cytotoxicity of tumor-specific CTL (224). This evidence concerns the gene TLR2 and neoplasm.